Actavis (ACT) Price Target Raised to $254 at UBS

August 6, 2014 11:21 AM

UBS maintained a Buy rating on Actavis (NYSE: ACT) and raised its price target to $254.00 (from $237.00). The change ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found